82 results
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
15 Jan 15
Regulation FD Disclosure
12:00am
or approved for sale in the U.S.
Laboratory Services Breast specimen cytology Pharmacogenomics 8
9 2015 Sales & Marketing Strategy for Collection … for ForeCYTE only.
10 2015 Sales & Marketing Strategy for Diagnostic Services A Service/Partner Specific Program Additional Services/Partners
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
23 Sep 14
Update on its ForeCYTE Breast Aspirator and its FullCYTE Breast Aspirator
12:00am
and submit a new 510(k) notification for the ForeCYTE Breast Aspirator to the FDA.
Outside the United States, Atossa’s commercial strategy is to obtain … ForeCYTE device will soon be available for commercial marketability in Europe. Our strategy to commercially launch our devices remains on track and we
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
7 Nov 22
Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
4:00pm
strategy to develop CAR-T therapies or adjacent opportunities within the immuno-oncology space.
Completed dosing in both Part B and Part C (of four … to initiate the study during the fourth quarter of this year. We are re-aligning our strategy to address new avenues in the field of oncology. We have
CORRESP
ATOS
Atossa Therapeutics Inc
19 Oct 12
Correspondence with SEC
12:00am
, intellectual property portfolio, business strategy, expected timetables for your existing product lines and the additional steps necessary … purchase complements the Company’s current business, including its allocation of resources, intellectual property portfolio, business strategy
8-K
ATOS
Atossa Therapeutics Inc
9 Nov 23
Departure of Directors or Certain Officers
9:00am
investment strategy, asset allocation, manager selection and portfolio construction. Mr. Finn is also a Founding Partner of Scientia Ventures
8-K
EX-99.1
t2ml4ngvmt0l2
13 May 20
Atossa Therapeutics Announces First Quarter 2020 Financial Results and Provides Company Update on COVID-19 HOPE and Endoxifen Programs
9:30am
8-K
EX-99.1
oct1xf8
12 Aug 14
Atossa Genetics Announces Second Quarter 2014 Financial Results
12:00am
8-K
EX-99.1
4dyjxfzj
13 Aug 21
Atossa Therapeutics Announces Second Quarter 2021 Financial Results - Provides Corporate Update and Information about Upcoming Stockholder Meeting
9:30am
CORRESP
z2zd3zcbejvzl7j0qy5
11 Jun 12
Correspondence with SEC
12:00am
8-K
EX-99.1
29ojznbxfffh7fbspuiz
14 Aug 23
Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
8:30am
POS AM
04f9ghyx a3axaqv
15 Apr 14
Prospectus update (post-effective amendment)
12:00am
424B3
2id5tv94hm5qhd2
19 Apr 13
Prospectus supplement
12:00am
424B3
8t8fht
25 Sep 20
Prospectus supplement
5:00pm